• Dr Melody Caramins

    B.Med, PhD, FFSc, FRCPA

    Read full bio

    Special Interests
    • Oncology
    • Reproductive health

    Dr Melody Caramins

    National Director, Genetics
    B.Med, PhD, FFSc, FRCPA

    Dr Melody Caramins is the National Director of Genomics for the Pathology Division of Healius Limited. She is a nationally recognised expert in the field of genomics, holding both medical and scientific specialist qualifications. Dr Caramins began her career in 1991, in a clinical role before embarking on her training in genetic pathology in 2001. After training at the Royal Prince Alfred and Prince of Wales Hospitals, she became Australia’s first graduating fellow in genetic pathology in 2006 and was conferred a PhD in genetics in 2010.

    Dr Caramins is a conjoint senior lecturer in Pathology at the University of NSW and the current Chair of the Royal College of Pathologists Genetics Advisory Committee. She also sits on a range of committees influencing national testing standards, policy, professional practice, and translational activities. Her focus at Healius is on the translation of new genetic technologies and discoveries into clinical tests, particularly in the fields of oncology and reproductive health, facilitating the integration of genomics into routine clinical care.

  • Dr Kym Mina

    MBBS, PhD, FRCPA

    Read full bio

    Dr Kym Mina

    Clinical Director
    MBBS, PhD, FRCPA

    She began her journey in genetics in 2007 as WA’s first genetic pathology trainee, and was awarded her fellowship in 2012 having attained broad experience in both molecular and cytogenetics in laboratories in WA and NZ. Following a post-fellowship year in translation of whole exome sequencing to clinical practice, Dr Mina took up a Clinical Academic appointment at The University of Western Australia before moving to Sydney as the Director of Genetics at Douglass Hanly Moir Pathology.

    Dr Mina is the current Chair of the Royal College of Pathologists of Australasia’s Genetics Advisory Committee. She is involved in national committees and activities that promote quality provision of genomic testing. Dr Mina has longstanding involvement in teaching of undergraduate and postgraduate science and medical students and supervision of genetic pathology trainees, and is committed to providing education and support for the appropriate use of genomic testing in all aspects of medical practice.

  • Dr Peter Taylor

    PhD, FHGSA

    Read full bio

    Dr Peter Taylor

    Molecular Geneticist, Scientific Director
    PhD, FHGSA

    Dr Peter Taylor is a Molecular Geneticist with solid training in general pathology prior to commencing specialisation in 1986. Peter’s clinical interests include oncogenetics and neuromuscular genetics. Early in his career, Peter performed research associated with the cloning of the estrogen receptor and its regulation and role in breast cancer at the University of New South Wales. Breast cancer genetics and the study of mutations associated with breast tumours has been an area of ongoing interest throughout his career. In his PhD thesis he reported the identification the cause of a newly described neuromuscular condition, determined the clinical utility of a comprehensive screening program for X-linked muscular dystrophy, and described the correlation between gene mutation location and cognitive defects in Duchenne muscular dystrophy. He has several highly read peer-reviewed papers and has contributed to numerous conference papers.

    Peter is a Fellow of the Human Genetics Society of Australia (FHGSA) was previous Chair for the Molecular Genetics Society of Australasia (2015-2017), and an examiner for the annual HGS Fellowship examinations. He is the Scientific Director for Molecular Testing at Genomic Diagnostics, Specialist Diagnostic Services, and his current role includes being the subject matter expert for the molecular genetics component of the Phoenix National LIS project.

  • Dr Nicole Chia

    PhD, FHGSA, FFSc (RCPA)

    Read full bio

    Dr Nicole Chia

    Clinical Scientist, Genetics Manager
    PhD, FHGSA, FFSc (RCPA)

    Dr Nicole Chia is a highly experienced clinical scientist, having begun working in the field of Clinical Cytogenetics in 1983. Nicole was awarded her PhD in 2016 and is a Fellow of the Royal College of Pathologists of Australasia’s Faculty of Science (FFSc., RCPA) and a Fellow of the Human Genetics Society of Australia (FHGSA). She is Adjunct Associate Professor in Diagnostic Pathology with the University of Canberra and Senior Lecturer at Queensland University of Technology.

     

    Nicole is Chief Scientist of the Genetics Department for QML Pathology, Specialist Diagnostic Services and currently manages an Australian wide diagnostic Cytogenetic Service. She has an international reputation in the field of Clinical Cytogenetics including a role as consultant to the International Standing Committee on Human Cytogenetic Nomenclature and has been an invited speaker at numerous international and national meetings. Over the years Nicole has served on numerous Boards, including Chief Examiner and Chair of the Cytogenetics Board of Censors for the Human Genetics Society.

  • Mark Williams

    FHGSA

    Read full bio

    Mark Williams

    Chief Scientist
    FHGSA

    Mark Williams is a clinical scientist and holds a Fellowship of the Human Genetics Society of Australasia (FHGSA) in Molecular Genetics. He is Chief Scientist at Genomic Diagnostics, leading a team providing NATA-accredited germline, somatic and reproductive genomic assays. Mark has over 20 years’ experience in diagnostic pathology and genomics in both public and private laboratories.

    Mark has a research appointment within the Developmental Disorders Group at Mater Research Institute-University of Queensland. Here, he is undertaking research relating to his PhD thesis entitled, “Novel variants in Angelman syndrome and related disorders: relationship to phenotype and neuronal function”.

    Mark is a member of the Human Genetics Society of Australasia (HGSA) Board of Censors, Diagnostic Genomics and is actively involved in the supervision of scientific and genetic pathology trainees. Mark has a clinical interest in improving patient care through translation and integration of genomic techniques into the clinical diagnostic laboratory.

Leading the way to improved health

Our dedicated team are committed to ensuring the best quality
results in the shortest turnaround time.